Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NSC-CRAd-S-pk7 in Newly Diagnosed High-Grade Glioma
NCT06169280Phase 1Active, not recruiting
- Sponsor
- Northwestern University
- Start
- Jun 2025
- Primary completion
- Dec 2029
- Modality
- Oncolytic Viruses, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NSC-CRAd-Survivin-pk7 in glioma, sponsored by Northwestern University. Primary endpoint: Dose-limiting toxicity at 8 weeks. Started Jun 2025; status: active, not recruiting.
02
Drugs
NSC-CRAd-Survivin-pk7
03
Conditions
glioma
Beyond the preview
Go deeper on NCT06169280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06169280.